Dana-Farber Cancer Institute | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana-Farber Cancer Institute

Diet Influences Survival After Stage III Colon Cancer, Dana-Farber Study Finds

June 13, 2025

Article

A Dana-Farber study shows that an anti-inflammatory diet could extend overall survival after treatment for stage III colon cancer.

T-DXd Plus Pertuzumab Displays Significant PFS Benefit Over SOC Therapy in Frontline HER2+ Advanced Breast Cancer

June 10, 2025

Article

Sara M. Tolaney, MD, MPH, discusses data showing that T-DXd plus pertuzumab improved PFS vs SOC THP in first-line HER2-positive breast cancer.

Collaborative Structural Reforms Represent a Way Forward for Oncology Innovations: With Elizabeth Mittendorf, MD, PhD, MHCM

June 09, 2025

Podcast

Dr Mittendorf shares how ASCO plans to address the implications of federal research funding cuts and how structural reforms may bolster oncology progress.

SERENA-6 Introduces Potential New Paradigm of Early ESR1 Mutation Detection to Delay Progression in HR+ Breast Cancer

June 09, 2025

Article

Erica L. Mayer, MD, MPH, discusses the implications of data from the SERENA-6 trial for ESR1 testing in hormone receptor–positive breast cancer.

Dr Sammons on the Significance of DESTINY-Breast09 for the HER2+ Breast Cancer Treatment Paradigm

June 05, 2025

Video

Sarah Sammons, MD, contextualizes the importance of T-DXd plus pertuzumab within the evolving ADC arsenal for HER2-positive breast cancer.

Dr Mittendorf Charts Vision as ASCO President-Elect to Advance Multidisciplinary Care and Research Equity

June 05, 2025

Article

Elizabeth Mittendorf, MD, PhD, shares her ASCO priorities: expanding trial access, strengthening teams, and advancing global, evidence-based oncology care.

Darolutamide Plus ADT Confers HRQOL Benefits in Metastatic Hormone-Sensitive Prostate Cancer

June 03, 2025

Article

A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Dr Tolaney on the PFS Benefit With First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 02, 2025

Video

Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Multidisciplinary Collaboration and Mentorship Lay the Foundation for a New Chapter of ASCO Leadership: With Elizabeth Mittendorf, MD, PhD, MHCM

June 02, 2025

Podcast

Dr Mittendorf discusses her priorities for advancing patient care and supporting up-and-coming oncology professionals during her 2026-2027 ASCO presidency.

Dr Sammons on the Efficacy of RLY-2608 Plus Fulvestrant in PIK3CA-Mutant HR+/HER2– Breast Cancer

June 02, 2025

Video

Sarah Sammons, MD, discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer.

First-Line T-DXd Plus Pertuzumab Yields PFS Benefit in HER2+ Advanced Breast Cancer

June 02, 2025

Article

Trastuzumab deruxtecan plus pertuzumab produced a statistically significant PFS improvement in frontline HER2-positive advanced breast cancer.

Adding Zilovertamab Vedotin to Standard Care Shows Strong ORR for DLBCL

May 31, 2025

Article

Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.

ASCENT-04 Data Support Sacituzumab Govitecan Plus Pembrolizumab as New SOC in PD-L1+ TNBC

May 31, 2025

Article

Frontline sacituzumab govitecan plus pembrolizumab improved PFS vs chemotherapy plus pembrolizumab in PD-L1+ metastatic triple-negative breast cancer.

Dr Richardson on Optimal Treatment Strategies for 1q–Amplified Multiple Myeloma

May 30, 2025

Video

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025

May 30, 2025

Article

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

Dr Tarantino on Directions for Prospective Research in HER2+ Metastatic Breast Cancer

May 27, 2025

Video

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.

New Study Unveils Potential Therapeutic Pathways for Aggressive Pediatric Brain Tumor

May 27, 2025

Article

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

Five Under 5: Top Oncology Videos for the Week of 5/18

May 25, 2025

Article

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

Dr Wang on Key Findings From a Study of the Tumor Microenvironment in ccRCC

May 23, 2025

Video

Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.

Dr Maroto-Martin on the Preliminary Efficacy of MZB1 TCR-Like CAR T-Cell Therapy in Myeloma

May 19, 2025

Video

Elena Maroto-Martin, PhD, discusses early efficacy data with an MZB1-targeted TCR-like CAR T-cell therapy in multiple myeloma and Waldenström macroglobulinemia.